UBS Group’s Rapport Therapeutics RAPP Stock Holding History

UBS Group’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.3M	Sell	151,174 -584	-0.4%	-$21.5K	﹤0.01%	3921
2026 Q1	$4.75M	Sell	151,758 -74,602	-33%	-$2.1M	﹤0.01%	4131
2025 Q4	$6.87M	Sell	226,360 -331,713	-59%	-$9.18M	﹤0.01%	3706
2025 Q3	$16.6M	Buy	558,073 +284,566	+104%	+$5.08M	﹤0.01%	2769
2025 Q2	$3.11M	Buy	273,507 +208,760	+322%	+$2.22M	﹤0.01%	4357
2025 Q1	$649K	Buy	64,747 +43,419	+204%	+$564K	﹤0.01%	5645
2024 Q4	$378K	Buy	21,328 +15,771	+284%	+$349K	﹤0.01%	6036
2024 Q3	$114K	Buy	5,557 +2,430	+78%	+$52.2K	﹤0.01%	6259
2024 Q2	$72.7K	Buy	+3,127	New	+$72.4K	﹤0.01%	6399

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

UBS Group's RAPP Position: Q2 2026 in Review

UBS Group reduced its Rapport Therapeutics (RAPP) stake by 0.38% in Q2 2026, selling an estimated $21.5K and leaving 151,174 shares worth $6.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3921.

UBS Group first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. The position peaked at $16.6M in Q3 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

UBS Group held 151,174 shares of Rapport Therapeutics worth $6.3M as of Q2 2026.
UBS Group sold 584 Rapport Therapeutics shares in Q2 2026, an estimated $21.5K.
Rapport Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3921 holding.
UBS Group first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
UBS Group's Rapport Therapeutics position peaked at $16.6M in Q3 2025.
160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.